Related Experiment Video

Updated: Aug 20, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted

Rebecca G Pomerantz1, Jennifer Rubin Grandis

  • 1Department of Otolaryngology, University of Pittsburgh School of Medicine and Cancer Institute, 200 Lothrop Street, Pittsburgh, PA 15213, USA.

Seminars in Oncology
|December 16, 2004
PubMed

Insights

Targeting the epidermal growth factor receptor (EGFR) offers a promising strategy for treating squamous cell carcinomas of the head and neck (SCCHN). Novel therapies targeting EGFR show potential for improved cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Aberrant signaling of the epidermal growth factor receptor (EGFR) is crucial in head and neck squamous cell carcinoma (HSCSC) development.
  • High EGFR expression in HSCSC correlates with poor prognosis, making it a specific therapeutic target.
  • EGFR is a transmembrane protein that regulates intracellular signals in epithelial cells.

Purpose of the Study:

  • To review novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) for head and neck squamous cell carcinoma (HSCSC).
  • To discuss the role of EGFR in carcinogenesis and its potential as a specific therapeutic target.
  • To evaluate the efficacy and safety of EGFR-targeted therapies in HSCSC treatment.

Main Methods:

  • Review of molecular signaling pathways involved in cellular transformation.
  • Analysis of EGFR expression levels in cancerous versus normal tissues.
  • Evaluation of therapeutic strategies including monoclonal antibodies, toxin conjugates, tyrosine kinase inhibitors, and antisense strategies.
  • Clinical assessment of EGFR-specific therapies in patients with SCCHN.

Main Results:

  • EGFR-specific monoclonal antibodies and tyrosine kinase inhibitors exhibit low toxicity in SCCHN patients.
  • Targeting EGFR extracellularly can be achieved with antibodies or toxin conjugates.
  • Intracellular EGFR targeting utilizes specific tyrosine kinase inhibitors.
  • Antisense strategies block EGFR production by targeting mRNA.
  • Combined EGFR-targeted therapies with standard treatments show additive or synergistic antitumor effects.

Conclusions:

  • EGFR is a validated and specific therapeutic target for head and neck squamous cell carcinoma (HSCSC).
  • Various strategies targeting EGFR, including antibodies and kinase inhibitors, are effective and well-tolerated.
  • Combination therapies involving EGFR-targeted agents hold promise for enhanced SCCHN treatment outcomes.

More Related Videos

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.